ClinicalTrials.gg
CompletedNCT01163721Updated Sep 23, 2013Results posted

Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

A Phase 2 interventional study of Ranolazine and Placebo in Diabetes Mellitus, Type 2, sponsored by Gilead Sciences. Completed at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-09-23.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ranolazine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Ranolazine · Diabetes Mellitus, Type 2.

Enrollment
5th of 11
80 · median 47
Started
2010
the only one that year
Phase 2
Only one
of the 11
Registered
1st of 11
by date
Lead sponsor
9 of 11
Gilead Sciences

Among the 11 studies testing ranolazine in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is the only one that started in 2010, is the only one in phase 2, and was the 1st registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 11 studies testing ranolazine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About ranolazine

Ranolazine: first FDA approval 2006 (RANEXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing ranolazine in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This study enrolled participants with inadequately controlled type 2 diabetes mellitus (T2DM) despite non-insulin antidiabetic therapy in addition to diet and exercise, and would have benefited from additional control of blood glucose levels. The study assessed the metabolic effects of ranolazine, including its effect in lowering glycosylated hemoglobin A1c (HbA1c), and lowering glucose while fasting, and following a meal (postprandial).

Participants were randomized in a 1:1 ratio to receive ranolazine or placebo, and were stratified by HbA1c ≤ 7.5% or > 7.5%. Enrollment was to include no more than two-thirds of participants with baseline HbA1c ≤ 7.5%. Other than glucose values, efficacy endpoint results remained blinded during the study; for safety purposes, the investigator was to be alerted of severe hyperglycemia or hypoglycemia.

Participants were instructed to maintain logs of their physical activity/exercise (Subject Activity Assessment) and study drug dosing (Dosing Log).

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Type 2 diabetes mellitus
  • T2DM
  • Ranolazine
  • Ranexa
  • HbA1c
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant with T2DM on stable non-insulin antidiabetic therapy in addition to diet and exercise
  • (BMI) ≥ 25 kg/m\^2 and ≤ 40 kg/m\^2
  • 7 - 11%
  • Ability and willingness to maintain a complete and accurate Subject Activity Log during the course of the trial
  • Female of must have agreed to use effective methods of
  • Ability to understand and willing to sign written

Exclusion criteria

Exclusion Criteria:

  • Type 1 Diabetes Mellitus (T1DM)
  • T2DM with history of or current insulin therapy. Prior use during pregnancy or gestational diabetes was acceptable.
  • History of ketoacidosis or ketosis-prone diabetes
  • complications of diabetes that in the judgment of the investigator would have made participant unsuitable to participate in this trial
  • History of a severe episode of hypoglycemia
  • Change in non-insulin antidiabetic therapy in addition to diet and exercise \< 2 months prior to screening
  • Any clinically significant cardiovascular event \< 2 months prior to screening
  • Clinically significant, inadequately controlled or unstable hypertension
  • Hospitalization \< 2 months prior to screening
  • Major surgery \< 3 months prior to screening
  • Weight loss medication (prescription or non-prescription) \< 2 months prior to screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Ranolazine

    Participants were randomized to receive ranolazine for 12 weeks.

    Drug: Ranolazine

  • Placebo comparator
    Placebo

    Participants were randomized to receive placebo to match ranolazine for 12 weeks.

    Drug: Placebo

Interventions

  • Ranolazine ER 1000 mg (two 500 mg tablets) administered orally twice daily

    Also known as: Ranexa®

  • DrugPlacebo

    Placebo to match ranolazine administered orally twice daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12

    HbA1c is a blood test to measure blood sugar control over the prior 3-month period. The last observation carried forward (LOCF) method was used: the last observed post-baseline measurements prior to Week 12 carried forward for participants with no available Week 12 values. Participants were summarized according to the actual treatment received regardless of the allocated treatment.

    Time frame: Baseline to Week 12

  2. Change From Baseline in 2-hour Postprandial Serum Glucose at Week 12 Following a Standardized Meal

    2-hour postprandial serum glucose was defined as the average of serum glucose measurement at 120 minutes and 125 minutes following a standardized meal. The LOCF method was used. Participants were summarized according to the actual treatment received regardless of the allocated treatment.

    Time frame: Baseline to Week 12

  3. Change From Baseline in Fasting Serum Glucose at Week 12

    Serum glucose was measured following an overnight fast. The LOCF method was used. Participants were summarized according to the actual treatment received regardless of the allocated treatment.

    Time frame: Baseline to Week 12

07

Results

Posted Sep 23, 2013

Participant flow

Participants with type 2 diabetes mellitus (T2DM) were enrolled in a total of 9 study sites in the United States. The first participant was screened on 22 June 2010. The last participant observation was on 15 November 2010.

Participant flow — Overall Study
MilestoneRanolazinePlacebo
Started3941
Completed3129
Not completed812
Withdrew: Adverse event56
Withdrew: Withdrawal by subject34
Withdrew: Lost to follow-up01
Withdrew: Physician decision01

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12

HbA1c is a blood test to measure blood sugar control over the prior 3-month period. The last observation carried forward (LOCF) method was used: the last observed post-baseline measurements prior to Week 12 carried forward for participants with no available Week 12 values. Participants were summarized according to the actual treatment received regardless of the allocated treatment.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · percent of HbA1c in blood
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12
percent of HbA1c in bloodRanolazinePlacebo
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12-0.61 ± 0.142-0.08 ± 0.142
Statistical analysis
  • Ranolazine vs Placebo · ANCOVA · p = 0.010 (P-value is from an Analysis of Covariance (ANCOVA) model with treatment as factor and baseline HbA1c value as covariate. Due to the exploratory nature of this study, there were no adjustments for multiplicity.) · Difference in least squares mean (lsm): -0.53 · 95% CI -0.93 to -0.13
PrimaryChange From Baseline in 2-hour Postprandial Serum Glucose at Week 12 Following a Standardized Meal

2-hour postprandial serum glucose was defined as the average of serum glucose measurement at 120 minutes and 125 minutes following a standardized meal. The LOCF method was used. Participants were summarized according to the actual treatment received regardless of the allocated treatment.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in 2-hour Postprandial Serum Glucose at Week 12 Following a Standardized Meal
mg/dLRanolazinePlacebo
Change From Baseline in 2-hour Postprandial Serum Glucose at Week 12 Following a Standardized Meal-26.6 ± 9.88-11.2 ± 9.63
Statistical analysis
  • Ranolazine vs Placebo · ANCOVA · p = 0.234 (P-value is from an ANCOVA model with treatment and baseline HbA1c stratification as factors and baseline value as covariate.) · Difference in lsm: -15.4 · 95% CI -41.0 to 10.2
PrimaryChange From Baseline in Fasting Serum Glucose at Week 12

Serum glucose was measured following an overnight fast. The LOCF method was used. Participants were summarized according to the actual treatment received regardless of the allocated treatment.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Serum Glucose at Week 12
mg/dLRanolazinePlacebo
Change From Baseline in Fasting Serum Glucose at Week 122.0 ± 7.214.5 ± 6.83
Statistical analysis
  • Ranolazine vs Placebo · ANCOVA · p = 0.794 (P-value is from an ANCOVA model with treatment and baseline HbA1c stratification as factors and baseline value as covariate.) · Difference in least squares mean (lsm): -2.5 · 95% CI -21.1 to 16.2

Adverse events

Collected over Baseline through Week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranolazine—0/39 (0%)12/39 (30.8%)
Placebo—1/41 (2.4%)15/41 (36.6%)
Most frequent serious events
Most frequent serious events
EventRanolazinePlacebo
Musculoskeletal PainMusculoskeletal and connective tissue disorders0/391/41
Most frequent other events
Most frequent other events
EventRanolazinePlacebo
HyperglycaemiaMetabolism and nutrition disorders1/395/41
HypoglycaemiaMetabolism and nutrition disorders4/393/41
DiarrhoeaGastrointestinal disorders3/393/41
NauseaGastrointestinal disorders3/391/41
DizzinessNervous system disorders3/390/41
HeadacheNervous system disorders1/393/41
Abdominal painGastrointestinal disorders2/391/41
InsomniaPsychiatric disorders2/391/41
AstheniaGeneral disorders2/390/41

Baseline characteristics

Safety Analysis Set

Age Continuous
Age Continuous(years)RanolazinePlaceboTotal
Mean58 ± 10.158 ± 9.158 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)RanolazinePlaceboTotal
Female161632
Male232548
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RanolazinePlaceboTotal
Hispanic or Latino252853
Not Hispanic or Latino141327
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)RanolazinePlaceboTotal
White333972
Black516
Other112
Glycosylated hemoglobin (HbA1c)
Glycosylated hemoglobin (HbA1c)(percent HbA1c in blood)RanolazinePlaceboTotal
Mean8.41 ± 1.0788.51 ± 1.1638.46 ± 1.117
2-hour Postprandial Glucose
2-hour Postprandial Glucose(mg/dL)RanolazinePlaceboTotal
Mean253.1 ± 57.37271.5 ± 87.67262.5 ± 74.57
Fasting Serum Glucose
Fasting Serum Glucose(mg/dL)RanolazinePlaceboTotal
Mean153.7 ± 43.05172.7 ± 52.20163.4 ± 48.60
08

Study locations

9 sites
  • AMCR Institute
    Escondido, California 92026, United States
  • National Research Institute (NRI)
    Los Angeles, California 90057, United States
  • SeaView Research Inc.
    Miami, Florida 33126, United States
  • Orlando Clinical Research Center (OCRC)
    Orlando, Florida 32809, United States
  • Midwest Institute For Clinical Research Inc. (MICR)
    Indianapolis, Indiana 46260, United States
  • Vince and Associates Clinical Research
    Overland Park, Kansas 66212, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Rochester Clinical Research (RCR)
    Rochester, New York 14609, United States
  • Cetero Research
    San Antonio, Texas 78229, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 2 years 10 months after primary completion. A results delay was requested in Jul 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2010
First posted
Jul 16, 2010
Start
Jun 2010
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results delay requested
Jul 21, 2011
Results first posted
Sep 23, 2013
Last update
Sep 23, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01163721
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 16, 2010
Start date
Jun 2010
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Sep 23, 2013
Last update
Sep 23, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion